Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome

Effect of the Growth Hormone MAXOMAT ® on the Growth of Small Children and Adolescents (<-2 SD) Due to NOONAN's Syndrome

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00452725

Enrollment

Registered

2007-03-27

Start date

1997-10-31

Completion date

2010-07-31

Last updated

2010-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Noonan Syndrome

Brief summary

1. Clinical Objective : To improve the growth of these children 2. Genetic objective : A study of the genetics of the syndrome

Interventions

DRUGMAXOMAT ®, biosynthetic growth hormone

2 posologies according to age (children and adolescents) treatment is planned for a 2 year duration

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

3 Years to 15 Years

Healthy volunteers

Inclusion criteria

* Children and adolescents with Noonan's syndrome with a height \< -2 SD and no progressive cardiopathy

Exclusion criteria

* Age \< 3 years * Height ≥ -2 SD The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Design outcomes

Primary

Measure	Time frame
Evaluation of height : gain in height and rate of growth	at each visit (every 3 months) or every 6 months

Secondary

Measure	Time frame
Clinical and laboratory test safety	every 6 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026